CERACUITY, INC.

New York, NY · Founded 2016 · CIK 0001679014 · Biotech · Private

Small-molecule PLD1 inhibitors to restore autophagic flux and clear tau protein aggregates in Alzheimer's disease

ceracuity.com →
Grants
$499K
1 award
Sector median: 1
Raised
$3K
1 Form D · Jul 2016
123 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$2,500
Federal grantDepartment of Health and Human Services · Phase I · Novel regulation of autophagic flux for the treatment of Alzheimer's disease$499,272
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1488NOVOBIOTIC PHARMACEUTICALS, LLC——
1489Cellevate Inc.—$25K
1490Pinto Inc.—$20K
1491CERACUITY, INC.—$3K
1492ProtaBody, Inc.—$800
1493SynPhaGen, LLC——
1494MITOSENSE, INC.—$2.2M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 5 related persons
  • Karen DuffDirector
  • Stuart FeinerDirector · Executive Officer
  • Philip McCarthyDirector
  • Robin OffordDirector
  • A. Douglas PeabodyDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.